Fu R, Zhang L, Yang R. Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment. Br J Haematol 2013;163(3):295-302.
DOI: 10.1111/bjh.12530
Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S. Evidence That Essential Thrombocythemia is a Clonal Disorder with Origin in a Multipotent Stem Cell. Blood 1981;58(5):916-9.
DOI: 10.1182/blood.V58.5.916.916
Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 2020;95(12):1599-613.
DOI: 10.1002/ajh.26008
Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J 2018;8(2):1-11.
DOI: 10.1038/s41408-018-0054-y
Putti MC, Bertozzi I, Randi ML. Essential Thrombocythemia in Children and Adolescents. Cancers (Basel) 2021;13(23):6147.
DOI: 10.3390/cancers13236147
Kralovics R, Passamonti F, Buser AS, Teo S-S, Tiedt R, Passweg JR, et al. A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders. N Engl J Med 2005;352(17):1779-90.
DOI: 10.1056/NEJMoa051113
Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2. N Engl J Med 2013;369(25):2391-405.
DOI: 10.1056/NEJMoa1312542
Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL, et al. Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients. Am J Hematol 2014;89(8):E121-4.
DOI: 10.1002/ajh.23743
Finazzi MC, Carobbio A, Cervantes F, Isola IM, Vannucchi AM, Guglielmelli P, et al. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis. Leukemia 2015;29(5):1209-10.
DOI: 10.1038/leu.2014.343